Thalidomide-piperazine-Boc is utilized in the development of novel therapeutic agents, particularly in the field of targeted cancer treatments. Its structure allows for the inhibition of specific proteins involved in tumor growth and angiogenesis, making it a valuable component in the design of anti-cancer drugs. Additionally, it is employed in the synthesis of PROTACs (Proteolysis Targeting Chimeras), which are bifunctional molecules that degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. This chemical also finds application in immunomodulatory therapies, where it helps regulate the immune response in conditions such as multiple myeloma and other hematologic malignancies. Its Boc-protected piperazine moiety enhances stability and facilitates further chemical modifications, making it a versatile intermediate in medicinal chemistry research.